From feasibility to neuroanatomic validity of remote cognitive smartphone assessments in early Alzheimer’s disease
Kirsten I. Taylor, Arnaud M Wolfer, Irma T. Kurniawan, Miguel Veloso et autres
0 citationsnpj Digital Medicine
David Watson
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
16Publications signalées
153Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsIntracerebral and Subarachnoid Hemorrhage ResearchAmyotrophic Lateral Sclerosis ResearchPhosphodiesterase function and regulation
Publications récentes
Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes
John A. Hey, Susan Abushakra, Aidan Power, David Watson et autres
0 citationsDrugs
Correlations between Clinical and Brain Volume Effects of Oral Valiltramiprosate in APOE4/4 Homozygotes with MCI: Pre-specified Analyses of the Phase-3 APOLLOE4 78-Week Trial in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD) (P6-12.010)
Marwan Sabbagh, Susan Abushakra, Duygu Tosun, David Watson et autres
0 citationsNeurology
Safety and ARIA Analyses of Oral Anti-amyloid Oligomer Agent Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Results of the Phase 3 78-week APOLLOE4 Trial (S1.009)
Earvin Liang, Sharon Cohen, Marwan Sabbagh, David Watson et autres
0 citationsNeurology
Effects of Oral Valiltramiprosate on Clinical Efficacy, Safety, and Brain Volume Outcomes in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Topline Results of the 78-week Phase 3 APOLLOE4 Trial (P1-12.001)
Susan Abushakra, Sharon Cohen, Marwan Sabbagh, David Watson et autres
0 citationsNeurology
Safety and ARIA Results of the Oral Anti‐Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD
Patrick Kesslak, Susan Abushakra, David Watson, Earvin Liang et autres
0 citationsAlzheimer s & Dementia
Efficacy and Safety of Oral Valiltramiprosate in APOE4/4 Homozygotes with Early AD: Topline Results from the APOLLOE4 Phase 3 Trial
Aidan Power, Susan Abushakra, David Watson, Anton P. Porsteinsson et autres
0 citationsAlzheimer s & Dementia
Correlations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in the Pre‐Specified MCI Group: Subgroup Analysis from the 78‐Week APOLLOE4 Phase 3 Trial in APOE4/4 Homozygotes
Susan Abushakra, P. Murali Doraiswamy, Earvin Liang, Duygu Tosun et autres
0 citationsAlzheimer s & Dementia
Valiltramiprosate Effects on Microstructural Integrity of Grey and White Matter in APOE4/4 Homozygotes with Early AD and their Correlations to Clinical Outcomes: MRI Mean Diffusivity Results from the 78‐Week APOLLOE4 Phase 3 Trial
Earvin Liang, Susan Abushakra, P. Murali Doraiswamy, Duygu Tosun et autres
0 citationsAlzheimer s & Dementia
Transitioning from Clinical Trial to Clinical Practice for Long‐Term Lecanemab Treatment in Early Alzheimer’s Disease: Perspectives from an Alzheimer’s Disease Treatment Center
David Watson, Michael G Neam, Mark Stafford, Cynthia Bouchard et autres
1 citationAlzheimer s & Dementia
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
Susan Abushakra, Aidan Power, David Watson, Anton P. Porsteinsson et autres
20 citationsDrugs
TargetTau‐1: Design of a phase 2 trial to evaluate the efficacy, safety, and tolerability of BMS‐986446, an anti‐MTBR tau monoclonal antibody, in patients with early Alzheimer’s disease
Christopher H. van Dyck, Anja Kahl, Grigor Abelian, Mark Donovan et autres
5 citationsAlzheimer s & Dementia
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.